Physician profile
James Ray Bartay
NPI 1518055581
$3,279.01
in general payments reported to CMS, 2019-2025
24 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $134 · 2022: $573 · 2023: $1,224 · 2024: $504 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,971.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $377.50 | 2022-2025 | Mounjaro, Jardiance, Emgality |
| Amarin Pharma, INC. | $355.36 | 2019 | |
| Abbott Laboratories | $334.95 | 2019-2024 | Proclaim |
| Pfizer INC. | $285.14 | 2023-2025 | |
| Medtronic, INC. | $234.59 | 2024 | Kyphon Express II Kyphopak Tray, Linq II |
| Abbvie INC. | $170.35 | 2023 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $152.49 | 2023-2024 | |
| Organogenesis INC. | $146.05 | 2023 | Puraply |
| Novo Nordisk INC | $139.90 | 2023-2025 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $133.72 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $131.40 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $105.33 | 2022 | |
| Glaxosmithkline, LLC. | $103.84 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Cardiovascular Systems INC. | $103.62 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $99.62 | 2022-2023 | Farxiga |
| Inspire Medical Systems, INC. | $61.71 | 2024 | Inspire |
| Si-Bone, INC. | $59.51 | 2022 | |
| Exact Sciences Corporation | $55.36 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.23 | 2019-2023 | Xifaxan |
| Itamar Medical INC | $21.35 | 2023 | Watchpatone |
| Radius Health, INC. | $18.26 | 2023 | Tymlos |
| Astellas Pharma US INC | $15.52 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $14.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bartay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.